StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)

StockNews.com assumed coverage on shares of ObsEva (NASDAQ:OBSV) in a research report released on Monday. The firm issued a hold rating on the stock.

ObsEva Price Performance

ObsEva has a 12 month low of $0.08 and a 12 month high of $2.14. The company has a market capitalization of $7.94 million, a P/E ratio of -0.11 and a beta of 0.68.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.